REG - Ilika plc - Battery Patent Update

IlikaAnnouncement

08/10/2019 07:00

RNS Number : 0401P
Ilika plc
08 October 2019
 


Ilika plc
("Ilika" or the "Company")
 
Battery Patent Update
 
Ilika (AIM: IKA), a pioneer in solid-state battery technology, announces that it has been granted eight of its Stereax® solid-state battery patent filings in five patent jurisdictions.
 
Over the past two years, Ilika has seen substantial progress in the prosecution of this aspect of its patent portfolio at the Patent Offices of China, Korea, Japan, USA and Europe.  As a result, three of its patent families are significantly stronger, with eight related filings going to grant and notices of allowance being issued for a further four.
 
These patent filings protect the methods used to make Ilika's thin-film solid-state Stereax® cells. The Stereax® roadmap commenced with miniature batteries designed to meet the demands of powering wireless devices and has been extended to include large format cells for automotive. 
 
Ilika's CEO Graeme Purdy said: "Protecting Ilika's know-how relating to solid-state batteries is key to our ability to grow our business. We take this very seriously and employ a Vice President of Intellectual Property, who is seconded to the Company from an international firm of patent lawyers to manage this process for us. This strategy is validated by the continued stream of granted patents reinforcing our position."
 
 
 
For more information contact:
 




Ilika plc


 




Graeme Purdy, Chief Executive


Tel: 023 8011 1400




Steve Boydell, Finance Director


 




 


 




Liberum Capital Limited


Tel: 020 3100 2000




Andrew Godber, Cameron Duncan, William Hall


 




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 / ilika@walbrookpr.com




Lianne Cawthorne


Mob: 07584 391 303




Nick Rome


Mob: 07748 325 236




 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDUBRVRKOARRAA